Claritas Pharmaceuticals Inc V.CLAS.H

RE:Robert Farrell ~ President and CEO

[GajjarDr]

R-107 will play an important role in the fight against COVID-19, and vaccine-resistant variants of the COVID-19 virus. We intend to become a leader in the race to find a treatment for COVID-19, and we are well positioned to achieve this goal, stated Robert Farrell, President and CEO of Claritas. However, our goal is more ambitious than that: we intend to develop R-107 as a broad-spectrum antiviral drug for the treatment of, and possible prevention of, future viral outbreaks. We are working closely with the Salzman Group to develop R-107 to treat, and possibly prevent, COVID-19 infection, as well as influenza and common colds caused by adenovirus, coronavirus and influenza virus. Mr. Farrell continued, Nitric oxide has generally demonstrated the ability to inhibit viral replication of RNA viruses, and there is an extensive body of in vitro and in vivo data demonstrating the ability of nitric oxide to prevent the replication and transmissions of several of these viruses. Based on these data, we intend to develop our proprietary R-107 technology as a therapy for COVID-19 infection, as well as a therapy for other RNA viruses, including the influenza virus.